<DOC>
	<DOCNO>NCT00702845</DOCNO>
	<brief_summary>Clinical trial objective investigate efficacy safety single injection 100 Î¼g Org 36286 woman weigh 60 kg less induce multifollicular development control ovarian stimulation ( COS ) , use daily recFSH reference .</brief_summary>
	<brief_title>To Investigate Efficacy Safety Single Injection Org 36286 Ovarian Stimulation Using Daily Recombinant FSH Reference ( Ensure ) ( P05690/MK-8962-001 )</brief_title>
	<detailed_description>This randomize , double-blind , active-controlled , equivalence clinical trial investigate efficacy safety new treatment regimen Org 36286 , recombinant gonadotropin apply initiate sustain follicular stimulation COS Assisted Reproductive Technology ( ART ) . For regimen , patient receive single injection Org 36286 one week later , treatment continue daily recFSH day trigger final oocyte maturation . In reference group patient receive daily injection recFSH day trigger final oocyte maturation . Equivalence two treatment group number oocytes retrieved primary objective trial .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<criteria>Females couple indication COS IVF ICSI ; &gt; =18 &lt; = 36 year age time sign informed consent ; Body weight &lt; = 60 kg BMI &gt; = 18 &lt; = 32 kg/m^2 ; Normal menstrual cycle length : 2435 day ; Availability ejaculatory sperm ( use donate and/or cryopreserved sperm allow ) ; Willing able sign inform consent . History of/or current ( treat ) endocrine abnormality ; History ovarian hyperresponse ovarian hyperstimulation syndrome ( OHSS ) ; History of/or current polycystic ovary syndrome ( PCOS ) ; More 20 basal antral follicle &lt; 11 mm ( ovary combine ) measure USS early follicular phase ( menstrual cycle day 25 ) ; Less 2 ovary ovarian abnormality ( include endometrioma &gt; 10 mm ; visible USS ) ; Presence unilateral bilateral hydrosalphinx ( visible USS ) ; Presence clinically relevant pathology affect uterine cavity fibroid &gt; = 5 cm ; More three unsuccessful IVF cycle since last establish ongoing pregnancy ( applicable ) ; History non low ovarian response FSH/hMG treatment ; History recurrent miscarriage ( 3 , even unexplained ) ; FSH &gt; 12 IU/L LH &gt; 12 IU/L measure local laboratory ( sample take early follicular phase : menstrual cycle day 25 ) ; Any clinically relevant abnormal laboratory value base sample take screening phase ; Contraindications use gonadotropin ( e.g . tumor , pregnancy/lactation , undiagnosed vaginal bleeding , hypersensitivity , ovarian cyst ) ; Recent history of/or current epilepsy , HIV infection , diabetes , cardiovascular , gastrointestinal , hepatic , renal pulmonary disease ; Abnormal karyotyping patient partner ( karyotyping perform ) ; Smoking 5 cigarette per day ; History presence alcohol drug abuse within 12 month prior sign informed consent ; Previous use Org 36286 ; Use hormonal preparation within 1 month prior randomization ; Hypersensitivity concomitant medication prescribe part treatment regimen protocol ; Administration investigational drug within three month prior sign inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>In vitro fertilization</keyword>
	<keyword>Pharmacological effect drug</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormone Substitutes Hormone Antagonists</keyword>
	<keyword>Pharmacological Actions</keyword>
	<keyword>Randomized</keyword>
	<keyword>Multi-center</keyword>
	<keyword>Multi-national</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Active-controlled</keyword>
	<keyword>Equivalence</keyword>
</DOC>